PolymarketCerradoComprobar disponibilidadSin KYC2% de comisiónDatos de resolución verificadosCalibración aceptableEste mercado se resolvió: No
Resuelto: 11 jun 2026, 9:52
Resolución verificada por el proveedor
CoinRithm tiene evidencia del ganador y del momento de liquidación respaldada por el proveedor para este mercado.
Resultado Ganador
No
A 7 días
—
A 24 horas
8%
SorpresaProbabilidad implícita actual
No 100%+0.9pt
Calidad del mercado
22 / 100
Baja calidadVolumen 24h
799,3 €
Liquidez
—
Liquidez desconocidaCompra / Venta
- / 0.4%
Datos de mercado
Actualizado hace 70 días
Desactualizado4 jun 26, 19:3510 jun 26, 0:00
Cronología de Probabilidad
Yes0%
No100%
100%
0%
Reglas
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
